1. Home
  2. SLNG vs MGNX Comparison

SLNG vs MGNX Comparison

Compare SLNG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNG
  • MGNX
  • Stock Information
  • Founded
  • SLNG 2013
  • MGNX 2000
  • Country
  • SLNG United States
  • MGNX United States
  • Employees
  • SLNG N/A
  • MGNX N/A
  • Industry
  • SLNG Oil/Gas Transmission
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLNG Utilities
  • MGNX Health Care
  • Exchange
  • SLNG Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • SLNG 94.1M
  • MGNX 87.7M
  • IPO Year
  • SLNG N/A
  • MGNX 2013
  • Fundamental
  • Price
  • SLNG $4.87
  • MGNX $1.47
  • Analyst Decision
  • SLNG Strong Buy
  • MGNX Hold
  • Analyst Count
  • SLNG 1
  • MGNX 9
  • Target Price
  • SLNG $12.00
  • MGNX $5.33
  • AVG Volume (30 Days)
  • SLNG 12.2K
  • MGNX 2.6M
  • Earning Date
  • SLNG 08-06-2025
  • MGNX 08-05-2025
  • Dividend Yield
  • SLNG N/A
  • MGNX N/A
  • EPS Growth
  • SLNG 191.00
  • MGNX N/A
  • EPS
  • SLNG 0.08
  • MGNX N/A
  • Revenue
  • SLNG $70,861,000.00
  • MGNX $154,050,000.00
  • Revenue This Year
  • SLNG $8.97
  • MGNX N/A
  • Revenue Next Year
  • SLNG $6.90
  • MGNX N/A
  • P/E Ratio
  • SLNG $64.13
  • MGNX N/A
  • Revenue Growth
  • SLNG 7.30
  • MGNX 255.31
  • 52 Week Low
  • SLNG $3.71
  • MGNX $0.99
  • 52 Week High
  • SLNG $8.28
  • MGNX $5.77
  • Technical
  • Relative Strength Index (RSI)
  • SLNG 46.45
  • MGNX 52.93
  • Support Level
  • SLNG $4.40
  • MGNX $1.19
  • Resistance Level
  • SLNG $5.29
  • MGNX $1.47
  • Average True Range (ATR)
  • SLNG 0.38
  • MGNX 0.11
  • MACD
  • SLNG 0.00
  • MGNX 0.02
  • Stochastic Oscillator
  • SLNG 45.19
  • MGNX 87.69

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: